CMS-FDA RAPID Coverage Pathway: Fast-Track Medicare Coverage for Breakthrough Devices
On April 23, 2026, CMS and FDA announced the RAPID pathway — a new initiative that could deliver Medicare national coverage within 60–90 days of FDA authorization for eligible Breakthrough Devices. This guide explains eligibility requirements, how the pathway works, IDE study design implications, and what manufacturers must do to prepare.
What Is the RAPID Coverage Pathway?
On April 23, 2026, the Centers for Medicare & Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA) jointly announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway — a new initiative designed to dramatically accelerate Medicare coverage for certain FDA-designated Class II and Class III Breakthrough Devices.
The core promise: CMS aims to provide national coverage within 60 to 90 days of FDA market authorization, compared to approximately a year or more under the current National Coverage Determination (NCD) process. For manufacturers of innovative devices, this represents the most significant reimbursement reform in over a decade.
CMS Administrator Dr. Mehmet Oz described the pathway as "bringing our two agencies together earlier, cutting red tape for innovators, and helping beneficiaries access new, life-changing health technology faster." FDA Commissioner Marty Makary, M.D., M.P.H., characterized the agencies as "functioning as a single team to deliver life-saving Breakthrough Devices to American patients as soon as we know they work."
A proposed procedural notice will be published in the Federal Register, followed by a 60-day public comment period. The pathway becomes effective upon publication of the final notice.
Why RAPID Was Needed: The Coverage Gap Problem
Historically, medical device companies have faced a coverage gap — the time between FDA market authorization (clearance or approval) and when Medicare actually agrees to pay for the device. This gap has several causes:
- Sequential processes: FDA reviews safety and effectiveness first. Only after authorization does CMS begin its independent analysis of whether the device is "reasonable and necessary" for Medicare beneficiaries.
- Misaligned evidence: Clinical evidence generated for FDA review often does not perfectly match what CMS needs to make a coverage determination. This means manufacturers may need to conduct additional studies or analyses after FDA authorization.
- NCD timelines: A standard National Coverage Determination can take 9–15 months, including public comment periods and evidence review.
For Breakthrough Devices — products designated by FDA as offering significant advantages over existing options for life-threatening or irreversibly debilitating conditions — this delay meant that patients who could benefit most waited months or years for Medicare coverage.
AdvaMed President and CEO Scott Whitaker called the RAPID pathway "a positive step toward expanding Medicare beneficiaries' access to the FDA-authorized, safe, and effective breakthrough medtech they desperately need."
Eligibility Requirements
Not all Breakthrough Devices qualify for RAPID. The pathway has specific eligibility criteria:
Device Requirements
| Requirement | Details |
|---|---|
| FDA Breakthrough Designation | Must have active Breakthrough Device designation from CDRH |
| Device Class | Class III devices (any), or Class II devices participating in the Total Product Life Cycle Advisory Program (TAP) |
| Unmet Medical Need | Must address unmet medical needs among Medicare beneficiaries |
| IDE Study | Must be the subject of an Investigational Device Exemption (IDE) study |
| Medicare Enrollment | The IDE study must enroll Medicare beneficiaries |
| Agreed Outcomes | Clinical health outcomes studied must be agreed upon by both FDA and CMS |
Key Eligibility Breakdown
Class III Breakthrough Devices: All Class III Breakthrough Devices are eligible regardless of TAP participation. This includes PMA and De Novo devices designated as breakthrough.
Class II Breakthrough Devices: Only those participating in the FDA's Total Product Life Cycle Advisory Program (TAP) — initiated as a pilot under MDUFA V — are eligible for the RAPID pathway. Class II devices not in TAP do not qualify.
IDE Requirement: This is a critical gating factor. The device must be studied under an IDE that enrolls Medicare beneficiaries and evaluates clinical outcomes jointly agreed upon by FDA and CMS. This means the pathway is primarily relevant for devices that require or benefit from clinical investigation before market authorization.
How the RAPID Pathway Works
Step-by-Step Process
Early Engagement (Pre-IDE or During IDE Planning) Manufacturers with Breakthrough-designated devices engage with FDA through existing pre-submission (Q-Submission) processes. Under RAPID, CMS experts now join these early discussions to help define clinical evidence requirements relevant to Medicare beneficiaries.
Aligned Evidence Generation During the IDE study, clinical outcomes are designed to satisfy both FDA premarket review requirements and CMS coverage evidence needs. This eliminates the historical problem of evidence misalignment.
Parallel Review As the IDE study progresses and the manufacturer prepares the market submission, both FDA and CMS review the accumulating evidence. CMS begins its coverage analysis concurrently with FDA's safety and effectiveness review.
Synchronized Authorization and Coverage Proposal On the same day an eligible device receives FDA market authorization, CMS issues a proposed NCD. This triggers the statutorily required 30-day public comment period.
Final Coverage Determination After the comment period, CMS issues the final NCD. Under the streamlined timeline, this entire process from FDA authorization to final Medicare coverage could take approximately 60–90 days.
Comparison: Current vs. RAPID Timeline
| Stage | Current Process | RAPID Pathway |
|---|---|---|
| FDA Review | 6–18 months | 6–18 months (unchanged) |
| Evidence Alignment | Post-authorization gap analysis | Pre-authorized during IDE |
| CMS Evidence Review | 6–12 months after FDA authorization | Parallel with FDA review |
| Proposed NCD | ~9 months after authorization | Same day as FDA authorization |
| Public Comment | 30 days | 30 days |
| Final NCD | ~12–15 months after authorization | ~60–90 days after authorization |
IDE Study Design Implications
The RAPID pathway fundamentally changes how manufacturers should think about IDE study design:
Clinical Outcomes Must Serve Two Masters
Under RAPID, the IDE study must measure clinical health outcomes that both FDA and CMS agree are meaningful. This means:
- FDA's focus: Safety and effectiveness endpoints, typically measured as primary and secondary endpoints in the IDE protocol.
- CMS's focus: Health outcomes relevant to Medicare beneficiaries, which may include functional status, quality of life, healthcare utilization, and cost-effectiveness signals.
Practical Design Considerations
| Consideration | Implication |
|---|---|
| Endpoint selection | Choose endpoints that satisfy both FDA effectiveness criteria and CMS "reasonable and necessary" standards |
| Patient population | Must include Medicare-age beneficiaries (65+) or those with Medicare-eligible conditions |
| Study size | May need to be larger to adequately power CMS-relevant endpoints |
| Data collection | Should capture healthcare utilization, adverse events, and functional outcomes |
| Follow-up duration | CMS may require longer follow-up than FDA for coverage-relevant outcomes |
Relationship to Other Medicare Coverage Pathways
The RAPID pathway does not replace existing coverage mechanisms. It operates alongside:
- Standard NCD process: Available for any device, not limited to Breakthrough Devices
- Local Coverage Determinations (LCDs): Made by Medicare Administrative Contractors (MACs)
- Coverage with Evidence Development (CED): For devices needing additional evidence post-market
- Section 1862(a)(1)(A): The general "reasonable and necessary" standard that applies to all Medicare coverage decisions
RAPID is specifically for the Breakthrough Device population and uses the NCD mechanism, but with a pre-aligned evidence base and compressed timeline.
What RAPID Does NOT Do
It is important for manufacturers to understand the limitations:
- No automatic coverage: RAPID does not guarantee Medicare coverage. CMS still makes an independent determination based on the evidence.
- No exemption from NCD requirements: The statutory 30-day public comment period and CMS review processes still apply.
- No coverage mandate: The pathway speeds up the process but does not mandate a positive coverage decision.
- Limited to Breakthrough Devices: Companies without Breakthrough designation cannot use this pathway.
- IDE requirement limits applicability: Devices that do not require or would not benefit from an IDE study (e.g., many 510(k) devices) may not be able to use RAPID even with Breakthrough designation.
Strategic Implications for Manufacturers
For Companies with Breakthrough Designation
Engage CMS early: Contact CMS during pre-submission discussions with FDA. Request that CMS experts participate in Q-Submission meetings.
Design IDE protocols for dual purposes: Ensure that study endpoints capture both FDA safety/effectiveness data and CMS-relevant health outcomes.
Budget for broader evidence generation: The RAPID pathway may require larger studies or additional data collection to satisfy both agencies.
Prepare reimbursement strategy earlier: The compressed timeline means reimbursement strategy must be developed concurrently with regulatory strategy, not sequentially.
For Companies Seeking Breakthrough Designation
The RAPID pathway adds a new dimension to the Breakthrough Device designation value proposition. Beyond the FDA benefits (priority review, interactive communication, senior management engagement), Breakthrough designation now includes a potential pathway to accelerated Medicare coverage.
When preparing a Breakthrough designation request, consider:
- Whether the device addresses an unmet need in the Medicare population
- Whether an IDE study is planned or underway
- Whether the device will be Class II (in TAP) or Class III
- Whether clinical outcomes can be designed to serve both FDA and CMS purposes
How RAPID Replaces TCET
The RAPID pathway replaces CMS's prior Transitional Coverage for Emerging Technologies (TCET) pathway, which was capped at approximately five candidates per year. According to a senior CMS official, approximately 40 devices currently qualify for the RAPID pathway, with an additional 20 potentially eligible — a significant expansion over TCET's limited scope. CMS plans to pause TCET for new candidates as RAPID takes effect.
Key Differences: TCET vs. RAPID
| Feature | TCET | RAPID |
|---|---|---|
| Annual cap | ~5 devices | No stated cap (40+ currently eligible) |
| Device eligibility | Emerging technologies | Breakthrough Devices with IDE studies |
| Agency alignment | Limited CMS-FDA coordination | Deep CMS-FDA evidence alignment from IDE stage |
| Coverage timeline | ~12 months after authorization | Target 60–90 days after authorization |
However, as Lee Fleisher and other industry experts have noted, the RAPID announcement focuses on coverage (whether Medicare will pay) but says relatively little about reimbursement (how much Medicare will pay). Hospitals and health systems must still receive adequate reimbursement that covers the actual cost of the device. Coverage alone does not guarantee adoption.
Frequently Asked Questions
Is RAPID available for 510(k) devices?
RAPID is available for Class II Breakthrough Devices, but only those participating in the FDA's TAP program. Most 510(k) devices are Class II, but relatively few have Breakthrough designation and TAP participation simultaneously.
Does RAPID apply to drugs or biologics?
No. RAPID is specifically for medical devices designated as Breakthrough Devices under the FDA's Breakthrough Devices Program.
What if CMS does not agree with the proposed coverage?
CMS still makes an independent coverage determination. If CMS determines the evidence does not support coverage, the device may still be eligible for coverage through other pathways (LCD, CED, or claim-level coverage).
How does RAPID interact with NTAP?
The New Technology Add-on Payment (NTAP) is a separate Medicare payment mechanism for hospitals using new, costly technologies. A device going through RAPID could also qualify for NTAP, providing additional payment incentives during the initial adoption period.
When does RAPID become effective?
The pathway will become effective upon publication of the final procedural notice in the Federal Register, following the 60-day public comment period. Manufacturers should begin planning now but cannot formally enter the pathway until it is finalized.
Key Takeaways
- The RAPID pathway could reduce the time from FDA authorization to Medicare coverage from 12+ months to 60–90 days for eligible Breakthrough Devices.
- Eligibility requires FDA Breakthrough Designation, Class III status (or Class II with TAP participation), and an IDE study enrolling Medicare beneficiaries.
- The pathway aligns FDA and CMS evidence requirements during the IDE stage, eliminating the historical coverage gap caused by evidence misalignment.
- RAPID does not guarantee coverage — CMS still makes an independent reasonable and necessary determination.
- Manufacturers should engage CMS early in the development process and design IDE protocols that serve both regulatory and reimbursement objectives.
Sources: FDA Press Announcement (April 23, 2026); CMS Press Release (April 23, 2026); Orrick Herrington & Sutcliffe LLP analysis (April 24, 2026); Foley Hoag LLP analysis (April 24, 2026); RAPS analysis (April 23, 2026); MedTech Dive (April 17, 2026); Medical Design & Outsourcing (April 2026); STAT News (April 23, 2026).